Design Therapeutics Inc
DSGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$913.75M
Close$
$0.27
98% downside
Current Fair Value
98% downsideOvervalued by 98% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $913.75 Million |
|---|---|
| Enterprise Value | $902.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 1.66 |
| Outstanding Shares | 62,505,340 |
Return
| Return on Equity | -35.07% |
|---|---|
| Return on Assets | -32.91% |
| Return on Invested Capital | -41.28% |
Valuation & Multiples
| P/E Ratio | -12.4 |
|---|---|
| PEG | -218.67 |
| Price to Sales | - |
| Price to Book Ratio | 4.51 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.73 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 1,553,900▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 69.72%▲ 7.88% |
|---|---|
| Total Invested | $630.38M▲ 55.99% |
| Investors Holding | 141▲ 17.00% |
ESG Score
No data
About Design Therapeutics Inc
15 employeesDesign Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, foll...